CurrentCignaPolicy 0531

Surgical treatments for lymphedema and lipedema (liposuction, lipectomy, microsurgical procedures, vascularized lymph node transfer)

Defines medical necessity criteria, exclusions, and background for surgical treatments of lipedema and lymphedema (including liposuction, lipectomy, excisional/debulking procedures, microsurgical lymphatic bypasses, and vascularized lymph node transfer) for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicySurgical treatments for lymphedema and lipedema (liposuction, lipectomy, microsurgical procedures, vascularized lymph node transfer)

Policy CodePolicy 0531

Change TypeRevisions (coverage additions and exclusions; EIU clarifications)

Effective Date

Next Review Date

Key ActionSubmit photographs confirming bilateral symmetric adiposity and document at least three months of failed conservative therapy, objective measures (volumetry/lymphoscintigraphy), and postoperative compression commitment when requesting coverage.

POLICY UPDATE CHANGES

Revised policy statement for lipedema to include hips and buttocks.

Added not covered policy statement for treatment of lipedema in the trunk, abdomen, or back.

Revised policy statement for microsurgical treatment to add lymph node-to-vein anastomosis (LVNA) to list of examples.

Removed tissue transfer (e.g. omental or mesenteric flap) and the word 'treatment' from the EIU statement.

Added not covered statement for the procedure Axillary Reverse Mapping/Reverse Lymphatic Mapping.

Title changed and updated to new template and formatting standards.

2Distinct covered conditions (Lipedema, Lymphedema)

>=3 moRequired conservative therapy duration before surgery

Coverage Summary

Coverage summary: This policy has a mixed coverage stance and defines medical necessity criteria for surgical treatment of lipedema of the extremities (including hips and buttocks) and for surgical treatment options for lymphedema (including excisional/debulking procedures, liposuction, microsurgical lymphatic bypasses and vascularized lymph node transfer).

Conditions/procedures covered (high-level):

- Lipedema of the extremities (including hips and buttocks): liposuction or lipectomy considered medically necessary when the specified clinical criteria are met (e.g., pain, easy bruising, nodularity, negative Stemmer sign unless coexisting lymphedema, failure of ≥3 consecutive months of conservative therapy, photographic confirmation of bilateral symmetric adiposity).

- Lymphedema surgical options: excisional/debulking procedures (including suction-assisted lipectomy) and physiologic microsurgical procedures such as lymphatico-venous anastomosis / lymphovenous bypass / lymph node-to-vein anastomosis (LVNA) and vascularized lymph node transfer (VLNT/VOLT) are considered medically necessary when policy quantitative and clinical criteria are met (e.g., functional impairment, volumetry differential thresholds, delayed lymphoscintigraphy, failure of ≥3 months conservative care, commitment to postoperative compression).

Procedures considered experimental/investigational/unproven (examples):

- Immediate lymphatic reconstruction for prevention of lymphedema (e.g., LYMPHA), prophylactic microsurgical lymphatico-venous anastomosis/lymphovenous bypass, and axillary reverse mapping (ARM)/reverse lymphatic mapping are labeled experimental/ investigational/unproven for prevention of lymphedema.

Not medically necessary distinctions: Liposuction/lipectomy for treatment of lipedema involving the trunk, abdomen, or back is considered Not Medically Necessary (policy explicitly distinguishes hips/buttocks as covered when criteria met).

Key thresholds and quick facts

Conservative therapy trial duration>= 3 consecutive months

Volumetry differential (dominant extremity)>10%

Volumetry differential (non-dominant extremity)>7%

Lymphoscintigraphy delayed transport time>= 60 minutes (considered delayed)

Minimal pitting criterion (example inclusion)no or minimal pitting (<5 mm) in some studies

Evidence quality for liposuction/lmicrosurgery outcomesOverall quality summarized as low / primarily observational / low-quality evidence

Excess volume threshold in Hoffner registry inclusionaffected arm ≥10% larger than unaffected arm

Medical Necessity Criteria

Lipedema - Liposuction / Lipectomy (Extremities, Hips, Buttocks)

Liposuction, (i.e., water jet-assisted liposuction, micro-cannular) or lipectomy for the treatment of lipedema of the extremities, including the hips and buttocks, is considered medically necessary when ALL of the following criteria are met:

ALL of the following

pain in the affected areas
easy bruising
nodularity of fat deposits in lipedema affected areas (dimpled or orange peel texture)
tenderness

Coding

Coding guidance summarymixed

No codes listed

Medically Necessary - Lipedema (extremities) / Lymphedema surgical codesCPTCovered

15832	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh.
15833	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg.
15834	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip.
15835	Excision, excessive skin and subcutaneous tissue (includes lipectomy); buttock.
15836	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm.
15837	Excision, excessive skin and subcutaneous tissue (includes lipectomy); forearm or hand.
15839	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area.
15877	Suction assisted lipectomy; trunk. (Medically necessary for hips/buttocks lipedema; trunk use limited or not medically necessary depending on area)
15878	Suction assisted lipectomy; upper extremity.
15879	Suction assisted lipectomy; lower extremity.

1–10 of 12

1/2

Not Medically Necessary - Lipedema trunk/back/abdomenCPTNot Covered

15830	Excision, excessive skin and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy.
15839	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area.
15847	Excision, excessive skin and subcutaneous tissue (includes lipectomy), abdomen (eg, abdominoplasty) (includes umbilical transposition and fascial plication).
15877	Suction assisted lipectomy; trunk. (Not medically necessary when used to report lipectomy/liposuction for the back, abdomen or trunk for treatment of lipedema)

Experimental/Investigational/Unproven - Prevention of lymphedema (immediate reconstruction/LYMPHA/ARM)CPTExperimental

38589	Unlisted laparoscopy procedure, lymphatic system.
38999	Unlisted procedure, hemic or lymphatic system.

Provider Actions & Billing Guidance

Documentation Required

Photographic confirmation for lipedema

Photographs must be submitted with the request to confirm the clinical appearance of lipedema. Photographic documentation should clearly show bilateral, symmetric adipose deposition in the affected extremities to support the diagnosis of lipedema and the anatomic distribution targeted for treatment.

Requirement: Photographs of bilateral symmetric adiposity in affected extremities (clinical photos showing distribution, symmetry, and characteristic signs such as 'cuff sign' or sparing of feet).

Prior Authorization

Prior authorization likely required

Prior authorization is likely required for surgical treatments (e.g., liposuction, lipectomy, microsurgical procedures) for lipedema or lymphedema. Submit supporting clinical documentation demonstrating that all applicable policy clinical criteria are met.

Background, Evidence & Definitions

Background (concise): Lipedema is a distinct, primarily female adipose disorder characterized by symmetric abnormal subcutaneous fat deposition of the extremities with tenderness, easy bruising, minimal pitting, and usually preserved lymphatic function in early stages; it may progress to lipolymphedema if lymphatic transport is overwhelmed. Lymphedema is abnormal accumulation of protein-rich interstitial fluid and fibroadipose tissue due to lymphatic dysfunction (primary or secondary) with progressive swelling, fibrosis, and recurrent infections.

Staging and diagnosis: Lipedema has descriptive staging (stage 1–4) based on skin and fat changes and progression to lipolymphedema. Lymphedema is staged using ISL (Stage 0–III) or Campisi scales; objective limb volume/circumference differences (e.g., ≥10% volume difference indicates lymphedema) and imaging are used to grade severity.

Diagnostic modalities: Imaging to confirm and characterize lymphedema includes lymphoscintigraphy (isotope lymphography; objective, reliable; imaging 30–120 minutes post-injection; transport time of 60 minutes is considered delayed), indocyanine green (ICG) lymphography, MR lymphography, duplex ultrasound and perometry/water displacement for volumetry.

Conservative therapy standards: Complete/complex decongestive therapy (CDT) — combining manual lymph drainage, compression therapy, exercise/mobilization, and skin care — is the standard first-line conservative management for lymphedema; lipedema patients also use CDT, compression, exercise, and weight management. Policy requires lack of response to at least three consecutive months of conservative management before many surgical options.

Guideline positions / evidence summary: Professional organizations and international guidelines acknowledge selected surgical options for properly selected patients: lymph-sparing liposuction is supported as a treatment option for lipedema when conservative measures fail, and physiologic (LVA/LVB, LVNA) and VLNT approaches have shown promising outcomes for lymphedema when performed by experienced surgeons; however, the evidence base is generally from observational studies, case series and low- to moderate-quality cohorts and guideline statements call for selective use and further high-quality trials. Detailed evidence synthesis and criteria follow in the policy.

Revision History

2025-09-15revisedLatest

Revised policy statement for lipedema to include hips and buttocks.

addedLatest

Added not covered policy statement for treatment of lipedema in the trunk, abdomen, or back.

revisedLatest

Policy Summary

PayerCigna

PolicySurgical treatments for lymphedema and lipedema (liposuction, lipectomy, microsurgical procedures, vascularized lymph node transfer)

Policy CodePolicy 0531

Change TypeRevisions (coverage additions and exclusions; EIU clarifications)

Effective Date

Next Review Date

On This Page

Lymphedema - Excisional (Debulking, Liposuction)

An excisional procedure (e.g., debulking, liposuction) for the treatment of lymphedema is considered medically necessary when an individual meets ALL of the following criteria:

ALL of the following

physical function impairment (e.g., difficulty ambulating, performing activities of daily living)
lack of response to at least three consecutive months of medical management (e.g., compression garments, manual lymphatic drainage)
postoperatively will continue to wear compression garments as instructed to maintain the benefits of treatment

Lymphedema - Quantitative/Clinical Criteria for Microsurgical/VLNT

When an individual meets ALL of the following criteria:

ALL of the following

ONE of the following signs and symptoms:
- physical function impairment (e.g., difficulty ambulating, performing activities of daily living)
- history of chronic or recurrent skin conditions (e.g., cellulitis, ulcerations)
- significant pain or weakness in the affected extremity
ONE of the following quantitative measurements:
- volumetry differential (circumferential measurements and/or perometry differential) >10% (if affected extremity is dominant extremity) or >7% (affected extremity is non-dominant extremity)>10%/>7%
- lymphoscintigraphy results show delayed transit time to first-level lymph nodes or a dermal back flow pattern
  Delayed transit time measured to first-level lymph nodes; abnormal if >60 minutes
lack of response to at least three consecutive months of medical management (e.g., compression garments, manual lymphatic drainage)
postoperatively will continue to wear compression garments as instructed to maintain the benefits of treatment

Procedures Considered Experimental/Investigational/Unproven

The following surgical procedures for the prevention of lymphedema are considered experimental, investigational or unproven:

ALL of the following

immediate lymphatic reconstruction (e.g., lymphatic microsurgical preventing healing approach [LYMPHA])
microsurgical lymphatico-venous anastomosis, lymphatic-capsular-venous anastomosis, lymphovenous bypass when used for prevention
axillary reverse mapping (ARM)/reverse lymphatic mapping

Codes Considered Medically Necessary for Microsurgical or Lymphatic Procedures

The following codes may be used to report microsurgical or other lymphatic procedures for lymphedema when the clinical criteria for such procedures are met:

ALL of the following

CPT 38589 — lymphatic imaging and/or surgical mapping procedures when used to report microsurgical treatments for lymphedema
CPT 38999 — unlisted procedure, used to report microsurgical lymphatic procedures when no specific CPT code exists and when criteria are met

Policy Revisions / Coverage Statements

Policy revisions / coverage statements summary (Revision History):

ALL of the following

This policy (0531) documents coverage criteria for surgical treatment of lipedema and lymphedema, including criteria for liposuction/lipectomy for lipedema of the extremities and hips/buttocks, exclusions for trunk/abdomen/back lipedema surgery, criteria for excisional and microsurgical/vascularized lymph node transfer procedures for lymphedema, quantitative thresholds for microsurgical/VLNT consideration, and coding guidance including codes considered medically necessary, not medically necessary, and experimental/investigational for prevention.
Revision history includes updates to clinical criteria, inclusion of LVNA among microsurgical examples, specification of volumetry thresholds (>10%/>7%), notation regarding lymphoscintigraphy delayed transit time (>60 minutes), and coding clarifications for CPT codes 15832-15879, 38589, and 38999.

Documentation Required

Conservative therapy documentation

Document prior conservative therapy efforts and response. The medical record must demonstrate an adequate trial of non‑surgical management before surgical consideration.

Conservative therapy documentation: record of at least three consecutive months of medical management (e.g., compression garments, manual lymphatic drainage, physical therapy) for the affected limb(s).
Conservative therapy requirement documentation: indication that conservative measures were used and insufficient to control symptoms (e.g., persistent pain, functional impairment, or lack of reduction in limb volume).
Prior conservative treatment documentation: dates, duration, specific modalities used (type/grade of compression garments, frequency/duration of manual lymphatic drainage), and objective notes on adherence and response.

Documentation Required

Preoperative assessment documentation

Preoperative assessment must include evaluation of symptom severity, functional impact, and exclusion of alternative causes.

Preoperative assessment documentation: history and physical exam findings (pain, easy bruising, nodularity, tenderness), negative Stemmer sign if applicable, absence of pitting edema unless coexisting lymphedema, and documentation of weight-loss efforts if relevant.
Objective measurement and staging: objective limb measurements (circumferential measurement, volumetry, or perometry) with documented differentials (>10% for dominant limb or >7% for non-dominant limb for lymphedema criteria) and clinical staging for lipedema/lipo-lymphedema.

Documentation Required

Policy-specific coverage documentation required

Provide documentation specific to policy-required coverage elements to support medical necessity.

Policy-specific coverage documentation required: evidence of pain, easy bruising, nodularity (dimpled/orange peel texture), tenderness, physical function impairment (e.g., difficulty ambulating or performing ADLs), lack of improvement with limb elevation, and lack of response to conservative therapy.
Include photodocumentation confirming bilateral symmetric adiposity for lipedema, and explicitly state if treatment involves trunk/abdomen/back (note: trunk/abdomen/back lipedema treatment is not covered).

Documentation Required

Claims must meet policy clinical criteria; trunk/abdomen/back lipedema treatment is not covered

Claims must meet all applicable policy clinical criteria and be supported by the documented medical record. Note that liposuction/lipectomy for lipedema of the trunk, abdomen, or back is not considered medically necessary and is not covered.

Coverage: Procedures for lipedema of the extremities (when all clinical criteria met) may be covered.
Not covered: Liposuction and/or lipectomy for lipedema of the trunk, abdomen, or back.

Topic / Finding	Summary / Value
Hoffner 2018 registry (liposuction + CCT)	Prospective registry n=105 non-pitting secondary arm lymphedema; mean postoperative reduction at 5 years 117% ± 26% vs healthy arm; inclusion: ≥10% excess arm volume, no/minimal pitting; no adverse events reported
Lamprou 2017 CSAL (leg)	Cohort n=88 unilateral end-stage primary/secondary leg lymphedema; primary group median preop volume diff 3686 ml → 761 ml at 2 years (79% reduction); secondary group median reduced to −38 ml (100% reduction) at 2 years
Garza 2022 simultaneous VLNT + LVB	Retrospective review n=220 patients; mean volume reduction 21.4% at 1 yr, 36.2% at 2 yrs; complication rate 12.7%; overall flap survival 99.6%
Basta et al. 2014 meta-analysis (microsurgery)	27 studies, n=1619; excess circumference reduction 48.8% ± 6.0%; excess volume reduction 56.6% ± 9.1%; 91.2% subjective improvement; 11.8% had no improvement
Carl et al. 2017 systematic review pooled surgical effect sizes	Reported mean excess volume reduction: liposuction 96.6%, LVA 33.1%, VLNT 26.4% (heterogeneous studies, limited quality)
Li et al. 2021 intra-abdominal VLNT pooled outcomes	Meta-analysis n=594; mean reduction rates ranged 0.38%–70.8% across studies; pooled donor-site complication rate 1.4%, recipient-site 3.2%
Combined VLNT + liposuction (Leppäpuska 2019 / other series)	Combined technique showed greater mean excess volume reduction (example: 87.7% in one series) and greater improvements in lymphoscintigraphy and cellulitis reduction vs LNT alone
Liposuction pooled comparative outcomes (Chang 2021)	Two comparative studies (stage II) pooled ~63.95% volume reduction vs controlled compression therapy (very low-quality evidence); multiple case series variably report substantial reductions
LVA (Rodriguez & Yamamoto 2022; systematic reviews)	Retrospective review n=229: upper extremity median volume reduction 67% (100% achieved reduction); lower extremity median 41% (86.8% achieved reduction); systematic reviews note heterogeneity and low-quality evidence but frequent objective/subjective improvements
Adverse events / complications summary	Reported AEs across studies: hyperpigmentation, cellulitis, skin paddle congestion, venous thrombosis, partial skin ulceration, seroma, hematoma, wound dehiscence, lymphatic leakage, numbness, pulmonary embolus, skin necrosis, donor-site complications (chyle leak, lymphorrhea). Garza cohort complications 12.7%
Cochrane / Markkula 2019 conclusion	Cochrane review: insufficient evidence to support widespread adoption of LVA or VLNT for prevention/treatment of breast cancer–related lymphedema; potential benefit when performed by expert surgeons
VLNT HRQoL and mixed evidence (Fish 2020, systematic reviews)	Limited prospective cohorts report favorable HRQoL at 12 months for VLNT; overall evidence heterogeneous and low/very low quality
Systematic reviews / Meta-analyses overall assessment (Chang 2021, Forte, others)	Multiple systematic reviews/meta-analyses find signal of benefit (volume/circumference reduction, decreased cellulitis, improved QoL) but emphasize poor study quality, heterogeneity, small samples, need for RCTs

Definitions / glossary (short):

- Stemmer sign: Negative when a fold of skin can be pinched and lifted at the base of the second toe or middle finger; positive (inability to pinch) indicates lymphedema; negative in lipedema unless coexisting lymphedema.

- CDT (Complex decongestive therapy): Noninvasive treatment combining manual lymph drainage, compression therapy, exercise/mobilization, and skin care; standard conservative therapy for lymphedema.

- CCT: Controlled compression therapy.

- CSAL: Circumferential suction-assisted lipectomy.

- LVA / LVB: Lymphaticovenous anastomosis / lymphovenous bypass (microsurgical anastomosis connecting lymphatic vessels to venules; also termed lymphatic capsular-venous anastomosis [LCVA]).

- VLNT / VOLT: Vascularized lymph node transfer / vascularized omental lymphatic transplant (microsurgical transfer of lymph node–containing flap, including intra-abdominal options such as omental/gastroepiploic or mesenteric flaps).

- ARM: Axillary reverse mapping / reverse lymphatic mapping — technique during axillary surgery to map/preserve arm lymphatics.

- LYMPHA: Lymphatic Microsurgical Preventing Healing Approach — immediate lymphatic reconstruction technique (proposed prophylactic lymphovenous anastomosis) to reduce postoperative lymphedema risk.

- LVNA: Lymph node-to-vein anastomosis (example of LVA/lymphovenous microanastomosis).